Allecra Therapeutics GmbH, a recent startup company that intends to develop two treatments to overcome multi-resistant, gram-negative bacteria, has raised €15 million in a series A financing from Edmond de Rothschild Investment Partners, Forbion Capital Partners and EMBL Ventures.
